Lithium gamolenate
Alternative Names: EF 13; Glamolec; LiGLA; Lithium-gamma linolenate; Lithium-GLALatest Information Update: 25 Jul 2000
At a glance
- Originator Scotia Pharmaceuticals [CEASED]
- Class Antineoplastics; Small molecules; Unsaturated fatty acids
- Mechanism of Action Prostaglandin synthase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Breast cancer; Colorectal cancer; Glioma; HIV infections; Lung cancer; Pancreatic cancer
Most Recent Events
- 25 Jul 2000 Discontinued-II for Colorectal cancer in United Kingdom (Unknown route)
- 28 Apr 1999 Discontinued-III for Pancreatic cancer in Australia (IV)
- 28 Apr 1999 Discontinued-III for Pancreatic cancer in New Zealand (IV)